Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination

Accorinti, Massimo; Saturno, Maria Carmela; Manni, Priscilla

doi:10.1080/09273948.2022.2027469

Cited by 14 publications

(13 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, we reported the second case in which VKHD occurred after adenovirus vectored vaccine ChAdOx1 nCoV-19 (AstraZeneca) [5] , the second case after mRNA-1273 (Moderna) vaccination [6] , and the third case of disease reactivation [7] , [8] .…”

Section: Discussionmentioning

confidence: 93%

“…Several VKHD cases, including new-onset disease or worsening of a previously controlled disease after COVID-19 vaccination, have been reported. In all reporting cases, related vaccines included the viral vector-based vaccine (ChAdOx1 nCoV-19, AstraZeneca) [5] , the mRNA-based vaccines (mRNA-1273, Moderna; and BNT162b2, Pfizer-BioNTech) [6] , [7] , [8] , and inactivated virus vaccines (CoronaVac, Sinovac and Vero cell, Sinopharm) [9] , [10] . Saranceno et al reported a case of a 62-year-old female diagnosed with VKHD after receiving a viral vector-based vaccine, ChAdOx1 nCoV-19.…”

Section: Discussionmentioning

confidence: 99%

“…In our second patient, the mRNA-based vaccine (mRNA-1273, Moderna) was associated with an activation of ocular inflammation in a previous well-controlled VKHD. In terms of reactivation, two cases have been described after mRNA-based vaccination (BNT162b2, Pfizer-BioNTech) [7] , [8] .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination

Rujkorakarn

Patamatamkul

2023

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination

Rujkorakarn

Patamatamkul

2023

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

“…A total of 65 studies were both qualitatively and quantitatively analyzed ( Table 1 ) [ 1 , 5 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 ,…”

Section: Resultsmentioning

confidence: 99%

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

et al. 2022

View full text Add to dashboard Cite

Numerous complications following COVID-19 vaccination has been reported in the literature, with an increasing body of evidence reporting vaccination-associated uveitis (VAU). In this systematic review, we searched six electronic databases for articles reporting the occurrence of VAU following COVID-19 vaccination. Data were synthesized with emphasis on patients’ characteristics [age, gender], vaccination characteristics [type, dose], and outcome findings [type, nature, laterality, course, location, onset, underlying cause, and associated findings]. Data are presented as numbers (percentages) for categorical data and as mean (standard deviation) for continuous data. Sixty-five studies were finally included [43 case reports, 16 case series, four cohort, one cross-sectional, and one registry-based study]. VAU occurred in 1526 cases, most commonly in females (68.93%) and middle-aged individuals (41–50 years: 19.71%), following the first dose (49.35%) of vaccination, especially in those who received Pfizer (77.90%). VAU occurred acutely (71.77%) as an inflammatory reaction (88.29%) in unilateral eyes (77.69%), particularly in the anterior portion of the uvea (54.13%). Importantly, most cases had a new onset (69.92%) while only a limited portion of cases had a reactivation of previous uveitis condition. In conclusion, although rare, uveitis following COVID-19 vaccination should be considered in new-onset and recurrent cases presenting with either acute or chronic events.

show abstract

“…Although VKH disease has a good prognosis with adequate treatment, autoimmune responses to melanocytes frequently play a role in its occurrence. 3 Several reports have described the recurrence of VKH disease after coronavirus disease 2019 (COVID-19) vaccination [4][5][6][7] ; therefore, this disease necessitates long-term monitoring. Additionally, several reports have stated that VKH disease recurrence and VKH disease itself may be correlated with COVID-19 vaccination.…”

Section: Introductionmentioning

confidence: 99%

Reactivation of previously controlled Vogt–Koyanagi–Harada disease more than 46 years following COVID-19 vaccination: a case study

Muto,

Sakamoto,

Imaizumi

et al. 2024

J Int Med Res

View full text Add to dashboard Cite

We report a case of Vogt–Koyanagi–Harada (VKH) disease that recurred 46 years after initial treatment. A 59-year-old woman presented with a 2-month history of bilateral vision blurring. She had received her third dose of coronavirus disease 2019 (COVID-19) vaccination 4 months before the onset of blurring. The best-corrected visual acuity (BCVA) was 1.0 in the right eye and 0.15 in the left eye at the initial visit. Iritis and synechia were observed between the lens and iris bilaterally. A sunset glow fundus was found in both eyes with no serous retinal detachments or disc hyperemia. The patient had a history of VKH disease and had been treated with whole-body corticosteroid administration at another hospital when she was 13 years old. The patient was diagnosed with VKH disease recurrence, and oral corticosteroid therapy and corticosteroid eyedrop treatment were initiated. The treatment response was good. At the time of this writing, recurrence had not been observed for 14 months, and the BCVA was 1.0 in both eyes. To our knowledge, this case represents the longest recorded interval of VKH disease recurrence in the literature to date. COVID-19 vaccination might be the cause of long-term well-controlled disease recurrence.

show abstract

Vogt-Koyanagi-Harada Relapse after COVID-19 Vaccination

Cited by 14 publications

References 26 publications

Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination

Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination

The Characteristics of COVID-19 Vaccine-Associated Uveitis: A Summative Systematic Review

Reactivation of previously controlled Vogt–Koyanagi–Harada disease more than 46 years following COVID-19 vaccination: a case study

Contact Info

Product

Resources

About